期刊名称：EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Experimental and Clinical Psychopharmacology seeks to promote the discipline of psychopharmacology in its fullest diversity. Psychopharmacology necessarily involves behavioral change, psychological processes, or their physiological substrates as one central variable and psychopharmacological agents as a second central variable. Such agents will include drugs, medications, and chemicals encountered in the workplace or environment. One goal of the journal is to foster basic research and the development of theory in psychopharmacology. Another is to encourage the integration of basic and applied research, the development of better treatments for drug abuse, and more effective pharmacotherapeutics. To this end, the journal publishes original empirical research involving animals or humans that spans (a) behavioral pharmacology research on social, behavioral, cognitive, emotional, physiological, and neurochemical toxicity; (b) descriptive and experimental studies of drug abuse, including its etiology, progression, adverse effects, and behavioral and pharmacological treatment; and (c) controlled clinical trials that, in addition to improving the effectiveness, range, or depth of application, will increase our understanding of psychological functions or their drug modulation. The journal also publishes theoretical and integrative analyses and reviews that promote our understanding and further systematic research in psychopharmacology. The journal also publishes papers in two other sections, Innovations and Remarks. Innovations is an occasional section that will highlight papers that establish a novel method, a novel result, a novel measure, or a new theory. Commentary may be solicited to address the nature of the innovation and to provide contrasting views. Remarks is another occasional section. The purpose of "remarks" is for brief commentary about important aspects of the field that have not been previously addressed or considered. Remarks could address either empirical or theoretical issues. Remarks are expected to be erudite, integrative, substantive, and thoughtful. Although case studies are not appropriate, occasional small-sample experiments with special populations may be considered. The journal is intended to be informative and useful to both basic and applied researchers and to practitioners operating in varied settings. Experimental and Clinical Psychopharmacology seeks to be the vehicle for the best research ideas and for integrating pharmacology and behavior.
Instructions to Authors
|
Submit five copies of manuscripts to the Editor:
Warren K. Bickel
Human Behavioral Pharmacology Lab
University of Vermont
Ira Allen School
38 Fletcher Place
Burlington, VT 05401-1419
Manuscripts should be submitted in quintuplicate, and all copies should be clear, readable, and on paper of good quality. An unusual typeface is acceptable only if it is clear and legible. In addition to addresses and phone numbers, authors should supply electronic mail addresses and fax numbers, if available, for potential use by the editorial office and later by the production office. Authors may also be requested to submit an electronic version of their manuscript on diskette. Authors should keep a copy of their manuscript to guard against loss.
Masked reviews are optional, and authors who wish masked reviews must specifically request them when submitting their manuscripts. Each copy of a manuscript to be mask reviewed should include a separate title page with authors' names and affiliations, and these should not appear anywhere else on the manuscript. Footnotes that identify the authors should be typed on a separate page. Authors should make every effort to see that the manuscript itself contains no clues to their identities.
Authors should prepare manuscripts for Experimental and Clinical Psychopharmacology according to the Publication Manual of the American Psychological Association (5th ed.). All manuscripts must include an abstract that contains a maximum of 120 words typed on a separate page. Formatting instructions (all copy must be double-spaced) and instructions on preparing tables, figures, references, metrics, and abstracts appear in the Publication Manual. All manuscripts are copyedited for bias-free language (see chap. 2 of the Publication Manual). To ensure the quality of all figures in the journal, authors should note that figures must be submitted as high-resolution laser prints or as photographed glossy prints, which must not exceed 8 x 10 in. (20 x 25 cm) in size; photomicrographs must not be mounted on cardboard or posterboard, and all parts of multiple-part figures must appear on the same laser or glossy print. Original color figures can be printed in color at the editor's discretion and provided the author agrees to pay half of the associated production costs; an estimate of these costs is available from the APA production office on request.
Experimental and Clinical Psychopharmacology publishes manuscripts that fall into one of four categories: Original Research Reports, Reviews of the Literature, Innovations in Psychopharmacology, and Remarks. Innovations in Psychopharmacology is an occasional section that will highlight papers that establish a novel method, a novel result, a novel measure, or a new theory. Commentary may be solicited to address the nature of the innovation and to provide contrasting views. Remarks, another occasional section, is for brief commentary about important aspects of the field that have not been previously addressed or considered. Remarks could address either empirical or theoretical issues. Remarks are expected to be erudite, integrative, substantive, and thoughtful.
Authors are required to obtain and provide to APA all necessary permissions to reproduce any copyrighted work, including, for example, test instruments and other test materials or portions thereof.
APA policy prohibits an author from submitting the same manuscript for concurrent consideration by two or more publications. In addition, it is a violation of APA Ethical Principles to publish "as original data, data that have been previously published" (Standard 8.13). As this journal is a primary journal that publishes original material only, APA policy also prohibits publication of any manuscript that has already been published in whole or in substantial part elsewhere. Authors have an obligation to consult journal editors concerning prior publication of any data upon which their article depends.
In addition, APA Ethical Principles specify that "after research results are published, psychologists do not withhold data on which their conclusions are based from other competent professionals who seek to verify the substantive claims through reanalysis and who intend to use such data only for that purpose, provided that the confidentiality of the participants can be protected and unless legal rights concerning proprietary data preclude their release" (Standard 8.14). APA expects authors submitting to this journal to adhere to these standards. Specifically, authors of manuscripts submitted to APA journals are expected to have their data available throughout the editorial review process and for at least 5 years after the date of publication.
Authors will be required to state in writing that they have complied with APA ethical standards in the treatment of their sample, human or animal, or to describe the details of treatment. A copy of the APA Ethical Principles may be obtained electronically or by writing the APA Ethics Office, 750 First Street, NE, Washington, DC 20002-4242.
APA requires authors to reveal any possible conflict of interest in the conduct and reporting of research (e.g., financial interests in a test procedure, funding by pharmaceutical companies for drug research). |
|
|
Editorial Board
Editor
Warren K. Bickel
University of Vermont
Consulting Editors
Robert L. Balster
Medical College of Virginia梀irginia Commonwealth University
Alan J. Budney
University of Vermont
Kathleen M. Carroll
Yale University School of Medicine
Marilyn E. Carroll
University of Minnesota, Twin Cities Campus
Howard D. Chilcoat
Johns Hopkins University
Thomas E. Eissenberg
Virginia Commonwealth University
Richard W. Foltin
New York State Psychiatric Institute
Stephen C. Fowler
University of Kansas
Charles P. France
University of Texas Health Science Center at San Antonio
Andrew J. Goudie
Liverpool University
Mark Greenwald
Wayne State University
Stephen J. Heishman
National Institute on Drug Abuse, Clinical Pharmacology Branch
Stephen T. Higgins
University of Vermont
Chris-Ellyn Johanson
Wayne State University
Thomas Kelly
University of Kentucky
G. Alan Marlatt
University of Washington, Seattle
Lisa A. Marsch
University of Vermont
Carolyn M. Mazure
Yale University
Edward V. Nunes
New York State Psychiatric Institute
Kenneth A. Perkins
University of Pittsburgh
Nancy M. Petry
University of Connecticut Health Center
Howard Rachlin
State University of New York at Stony Brook
Damaris J. Rohsenow
Brown University
Craig Rush
University of Kentucky
David Shurtleff
National Institute on Drug Abuse
Kenneth Silverman
Johns Hopkins University School of Medicine
Roger D. Spealman
Harvard Medical School—NERPRC
Maxine L. Stitzer
Johns Hopkins University
Eric C. Strain
Johns Hopkins University
Richard E. Tessel
University of Kansas
Stephen T. Tiffany
Purdue University
Rudy E. Vuchinich
Auburn University
Herbert Weingartner
National Institute Drug Abuse, Division of Basic Research
Jenny L. Wiley
Medical College of Virginia梀irginia Commonwealth University
James H. Woods
University of Michigan Medical School
Alice M. Young
Wayne State University
|
刊名字顺( Alphabetical List of Journals):
返回页首 